Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center provide fresh insights about how cancers evolve when they metastasize – insights that could aid in developing strategies to improve the effectiveness of treatment.
A clinical trial in patients with advanced breast cancer has found the use of liquid biopsy blood tests for early detection of a treatment-resistant mutation, followed by a new type of treatment, substantially extends the period of tumor control.
Using an algorithm they call the Krakencoder, researchers at Weill Cornell Medicine are a step closer to unraveling how the brain’s wiring supports the way we think and act.
The honor is presented annually, recognizing awardees on campuses across the SUNY system for their commitment to sustaining intellectual vibrancy, advancing the boundaries of knowledge, providing the highest quality of instruction and serving the public good.
A team of Cornell researchers is exploring how workplace tracking apps can be used not to surveil workers, but to help them build solidarity and improve their working conditions.
Imprint, an organization founded at Cornell Tech that is dedicated to decoding the body’s immune memory and uncovering the causes of chronic diseases, announced that it has raised over $15 million in funding.
A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine.
